News provided by Scripta Insights May 20, 2025, 08:00 ET New member app feature delivers trusted, clinician-backed guidance as millions face GLP-1 access setbacks after CVS Caremark drops Zepbound and WeightWatchers files for bankruptcy BOSTON, May 20, 2025 /PRNewswire/ -- Scripta Insights , the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans and their members to prescription savings, announces today its GLP-1 Navigator , a new resource in the Scripta member app that gives patients up-to-date, trusted information about GLP-1 medications in a centralized guide
Trademarks cost money, and when someone buys a generic version of semaglutide, that money doesnt go to Novo Nordisk
Disclosure: A licensed vendor partner will deliver this medicine to you
Their dual action makes them valuable options for individuals with Type 2 Diabetes and obesity
So you've jumped through the hoops, filed the appeal, and the final answer from Blue Cross Blue Shield is still no
Our comparison of tirzepatide oral vs
